Parabolic Drugs Ltd. announced unaudited earnings results for first quarter ended June 30, 2017. For the quarter, the company reported total revenue of INR 198.1 million compared to INR 111.5 million a year ago. Loss before exceptional and extraordinary items and tax was INR 121.6 million compared to INR 773.1 million a year ago. Loss before tax of INR 121.6 million compared to INR 773.1 million a year ago. Loss for the period from continuing operations was INR 126.0 million compared to INR 773.1 million a year ago. Loss for the period was INR 126.0 million or INR 2.04 basic and diluted per share before and after extraordinary items (not annualized) compared to INR 773.1 million or INR 12.49 basic and diluted per share before and after extraordinary items (not annualized) a year ago.